The standard treatment of acute promyelocytic leukaemia (APL), a clinically and biologically distinct variant of AML, includes both targeted transcriptional and differentiation therapy and greatly induces the atypical expression of TG2 in myelocytic cells, such as NB4 cells [4, 5]. This evidence concerns the gene TGM2 and acute promyelocytic leukemia.